Background-We describe the characteristics and outcomes of peripartum cardiomyopathy (PPCMP) patients who received durable mechanical circulatory support and compared it with other etiologies of advanced heart failure. Methods and Results-We analyzed 1258 women who were registered in Interagency Registry for Mechanically Assisted Circulatory Support between June 2006 and March 2012. Baseline characteristics, implant strategies, hemodynamics, echocardiographic data, and outcomes were compared. Ninety-nine women had PPCMP and 1159 had non-PPCMP as primary diagnosis. PPCMP women were younger (P<0.001), more likely to be blacks, and had less comorbidities than non-PPCMP patients. PPCMP women had better survival than non-PPCMP women (P=0.01) with a 2-year survival of 83%. Multivariable risk factor adjustment analysis showed that the improved survival was likely because of younger age and fewer comorbidities. At 36 months, a proportion of 48% PPCMP received heart transplantation. Recovery occurred at a frequency of 6% and 2% in the PPCMP and non-PPCMP groups (P=0.1). Adverse event rates were similar in PPCMP and non-PPCMP patients except for higher cardiac arrhythmias and respiratory failure in the non-PPCMP in the first 3 months post implant. Conclusions-PPCMP women who receive durable mechanical circulatory support have a better survival than women with non-PPCPM. The improved survival observed in PPCMP is likely related to their fewer comorbidities and younger age. Myocardial recovery was uncommon and less than half of women with end-stage PPCPM received heart transplantation after 3 years of mechanical support. (Circ Heart Fail. 2014;7:300-309.)
P eripartum cardiomyopathy (PPCMP) is a global disease with significant epidemiological variations according to geographic distribution. 1 In the United States, it occurs at an incidence rate of ≈2.5 to 5 cases per each 10 000 live births (mean, 3.1 per 10 000), with 1 case for every 3186 women delivering a baby. [2] [3] [4] [5] It is estimated that 1350 women in the United States are affected each year. 1 The pathogenesis of PPCMP remains unknown and as a result there are no specific preventive or therapeutic interventions for the management of this disease, other than general measures used in patients with other forms of cardiomyopathy. 6 Multiple reports reflect the reversibility of myocardial dysfunction in PPCMP, with ≈60% of patients improving and 45% normalizing their left ventricular (LV) function by 6 months after their diagnosis. 7, 8 In addition, a significant proportion of patients continue to improve LV function after 6 months. [8] [9] [10] In spite of its low incidence and reversibility with current medical therapy, in the United States, the reported mortality of PPCMP patients varied between 0% and 16.7%. 1, [3] [4] [5] 8 In addition, a recent review of the literature quoted transplant rates between 6% and 11%. 1 PPCMP is the fourth most frequent etiology, representing 5%, of heart transplantation in women. 11 PPCMP patients present not only with LV dysfunction but also with biventricular involvement. Those with hemodynamic compromise unable to be stabilized by medical therapy may require mechanical circulatory support (MCS). 12 Case reports and small case series provide limited information on the characteristics and outcomes of women with PPCMP who received ventricular assist devices. [12] [13] [14] Our objective was to establish the epidemiological characteristics, the type of devices used, the strategy of MCS at implant, and the outcomes of patients with PPCMP who received durable MCS.
Methods

Patient Population and Characteristics
The Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) is a prospective registry of approved durable MCS devices implanted in the United States. In-depth description of the registry has been published and is available at http:// www.INTERMACS.org. The INTERMACS protocol was approved by the National Institutes of Health, the Institutional Review Board at the Data Coordinating Center at the University of Alabama at Birmingham, and at the institutional review board of each participating hospital. In addition, the registry is monitored by an National Institutes of Health-appointed independent Observational Study Monitoring Board.
Our study population comprised all women, >14 years, entered in the INTERMACS registry who received MCS from June 23, 2006 , until March 31, 2012 . There were 1273 women who received primary prospective implants who met these inclusion criteria. Fifteen patients were excluded because they had an unspecified or unclear primary diagnosis, thus a total of 1258 women were included in the present study.
Baseline characteristics (epidemiological, laboratory, echocardiographic, and hemodynamic) were obtained for all patients including the duration of heart failure symptoms before the implantation, which was categorized as acute (<1 month), subacute (1 month to 1 year), or chronic (≥1 year). These time cutoffs were determined by the categorical data collected in INTERMACS.
The implantation strategy was categorized as bridge to transplant (BTT), if patients were listed at the time of MCS; bridge to candidacy (BTC), if patients were consider possible candidates for heart transplant but were not listed at the time of implantation; destination therapy (DT), if patients were not transplant candidates; and bridge to recovery (BTR), if the implanting center determined that there was a likelihood for explantation of the device.
Statistical Analysis
Baseline characteristics for the women enrolled in INTERMACS were stratified by primary diagnosis and within the PPCMP patients by the duration of heart failure symptoms before MCS. The statistical significance of differences between categorical variables was evaluated using the χ 2 test or Fisher exact test, and the difference between continuous variables was evaluated using 2 independent sample t test or 1-way ANOVA.
The difference in survival between pathogenic groups was analyzed using Kaplan-Meier plots, and survival curves were compared using the log-rank test with censoring for transplantation or device explant because of recovery. Competing outcome methodology was used to estimate the time-related probability of PPCMP patient outcomes. 15 Multivariable analysis in the parametric hazard domain was used to model preimplant risk factors for mortality for both early and constant hazards and to predict survival curves for the pathogenic groups with various characteristics. The hazard modeling methodology used has been described previously in detail. 16 Briefly, the method of maximum-likelihood is used to resolve ≤3× to event phases (early decreasing or peaking hazard, constant hazard, and late increasing hazard), with each phase scaled by a parametric function of concomitant variables. The simplest model that describes these phases, based on the likelihood ratio test, is determined from nested generic families of equations, including exponential, Weibull, Rayleigh, Gompertz, and Makem-Gompertz. Covariates used to predict survival were identified in a prior report 17 and included age, body mass index, mechanical ventilatory support, INTERMACS profile at the time of implantation, diabetes mellitus, dialysis at the time of implant, creatinine level, right heart dysfunction, right ventricular assist device support, right atrial pressure, bilirubin, ascites, history of prior cardiac surgery, concomitant surgeries at the time of MCS, and DT as implant strategy.
Adverse events were calculated as rate per month and stratified in early or late events if they occurred before or after 3 months from implantation, respectively. Adverse events were compared between the PPCMP and non-PPCMP groups using the likelihood ratio test for comparing linearized rates. Statistical significance was considered when P<0.05.
Results
One thousand two hundred fifty-eight women met the inclusion criteria. Ninety-nine patients had PPCMP, 771 had non-ischemic cardiomyopathy (NICMP), and 388 had ICMP. Given the survival of ICMP and NICMP were similar, for some analysis these patients were grouped as non-PPCMP (n=1159). Baseline characteristics are presented in Table 1 . PPCMP patients were significantly younger, more frequently blacks, and had less comorbidities than patients with other primary diagnosis. As might be expected in this younger cohort, the indication for device implantation was predominantly BTT or BTC as opposed to DT for the PPCMP group. PPCMP patients had a mean unadjusted survival at 1, 2 ,and 3 years of 85.3%, 82.7%, and 67.8% respectively, which was significantly better than the survival in non-PPCMP patients ( Figure 1 ). When survival analysis was performed in patients who received MCS, excluding DT patients, the differences favoring PPCMP patients were maintained (P=0.04). Comparison among DT patients was not possible because of the low number of patients with PPCMP who received MCS with this strategy. Unadjusted survival of PPCMP remained significantly better when compared with ICMP or non-ICMP patients ( Figure 2 ).
The characteristics of the PPCMP patients stratified by the duration of heart failure before the implantation of durable MCS are presented in Table 2 . Patients with acute and subacute heart failure were significantly younger than women with PPCMP presenting with chronic heart failure. Severity of illness was higher in the 18 PPCMP patients who had acute heart failure presentation as reflected by the fact that 50% of them were in cardiogenic shock (INTERMACS profile 1), 10 were on intra aortic balloon pump, 4 were supported by other devices, 6 were mechanically ventilated, and 2 were on extra corporeal membrane oxygenation at the time of implantation. A higher percentage of these patients required biventricular support. Despite this, only 2 patients in the acute subgroup died through the study period (both were on extra corporeal membrane oxygenation and mechanically ventilated at the time of durable MCS implantation).When stratified by duration of heart failure symptoms, no differences in postimplant survival was observed (P=0.5), despite the differences in acuity of illness. In addition, the patients with an acute presentation had a similar rate of transplantation compared with women with chronic heart failure. Recovery leading to explantation was a rare occurrence and was only observed in those with acute or subacute heart failure duration.
Competing outcomes in PPCMP versus non-PPCMP groups are shown in Figure 3A and 3B. At 1 year, a proportion of 55.9% and 51.8% of patients in the PPCMP and non-PPCMP groups remained alive on MCS (P=0.47), whereas a proportion of 29.8% and 24.4% of patients were transplanted in each group, respectively (P=0. 19) . At 2 years of follow up, in the PPCMP group, 23 patients were still alive on devices. Of these, 7 were BTT, 9 were BTC, and 7 were DT. At 36 months of device implantation, a proportion of 48% of PPCMP had received heart transplantation compared with 36.1% in the non-PPCMP group (P=0.01). Recovery was uncommon, with no differences between groups (P=0.1). There were 14 deaths on MCS in the PPCMP group. The primary cause of death included neurological (4), right ventricular failure (2), arrhythmias (1), bleeding (1), multiorgan failure (1), renal failure (1), respiratory failure (1), infection (1), and other circulatory causes (2). Competing outcomes were analyzed by implant strategy for the PPCMP cohort and are shown in Figure 4A and 4B. At 12 and 36 months, heart transplantation was achieved in a proportion of 41% and 58% of BTT and in 17.9% and 26% of BTC patients, respectively.
As outlined in the Methods section, previous analysis of >5000 patients enrolled in the INTERMACS registry 17 identified specific preimplant risk factors associated with increased mortality post device placement. Using these previously elucidated risk factors, a model was developed to predict survival of patients with PPCMP and non-PPCMP receiving durable MCS. Figure 5A shows the predicted survival when each variable in the model was set to the median value for each cohort. This resulted in a comparison of the average PPCMP patient to the average non-PPCMP patient. The predicted survival between the 2 groups is statistically different (P<0.01) and is comparable with the unadjusted actuarial survival shown in Figure 1 , indicating the model was reflective of (or fit) the observed results. Because of differences in clinical characteristics (such as age and burden of comorbidities) between the average PPCMP and average non-PPCMP patient, a second comparison was performed using this model in an effort to control for these baseline differences. In this second comparison, the variables in the model were set to the same median value of the overall cohort for both the PPCMP and non-PPCMP equations. This allowed for comparison of the independent effect of PPCMP on survival because all other variables were set to the same value in both cohorts. The result of this analysis is presented in Figure 5B , which shows that after controlling for all the risk factors except etiology, the predicted survival was no longer significantly different (P=0.07), suggesting the favorable clinical characteristics of the PPCMP patients and not the underlying etiology, accounted for most of the survival advantage. Adverse events rates are shown in Table 3 . The most common early (<3 months) adverse events in both groups were bleeding, infection, and rehospitalization, with similar rates in PPCMP and non-PPCMP groups. The rates of cardiac arrhythmias and respiratory failure were significantly higher in the non-PPCMP group. The most common late (≥3 months) adverse events in both groups were infection and rehospitalization, with no significant differences.
Discussion
Our study represents the largest and most comprehensive report to date on the characteristics and outcomes of end-stage PPCMP women who received durable MCS, providing insights that may be applied in clinical practice. We found that unadjusted survival of women who received MCS with PPCMP was significantly better compared with those with other heart failure diagnoses; however, this improvement in survival was likely because of younger age and fewer comorbidities.
PPCMP patients have unique characteristics compared with other forms of cardiomyopathy. It occurs with higher frequency among blacks and with a lower incidence in Hispanics. 4 Our report shows that 55% of patients with PPCMP who received durable MCS were blacks, and PPCPM is the cause of 13% of MCS implants in this population. The higher frequency of MCS in black women with PPCMP could be explained not only by its higher prevalence but maybe also because of the worse prognosis observed in blacks affected with this disease. 18 Patients with PPCMP are young, with epidemiological studies reporting a mean age of 33 years, 3 almost identical to our observation. We also showed that PPCMP who receive MCS were younger than other women receiving MCS with non-PPCMP. In addition, PPCMP had fewer comorbid conditions, such as diabetes mellitus, history of cancer, viral hepatitis, and peripheral vascular disease. This is not surprising as the prevalence of several of these comorbid conditions increases with age. Our analysis stratified the timing of presentation of patients with PPCMP into 3 different categories. Although these divisions were arbitrary, it is our opinion that it accurately described the chronicity of heart failure as noted by the progressive dilatation of the left ventricle. Women with an acute presentation were youngest with 50% classified as INTERMACS profile 1 (cardiogenic shock) at implantation. Despite their young age, only 16% received MCS as a BTT with most categorized as BTC, indicating that the treating physicians thought there was a barrier to transplantation or perhaps potential for recovery. In addition, these patients had the highest rate of biventricular assist device implantation (33%) indicative of concomitant right heart failure. Despite the markers of poor survival, including INTERMACS profile 19 and biventricular assist device support, 20 only 2 women died. Women presenting with subacute and chronic heart failure had incrementally fewer INTERMACS profile 1 patients and less biventricular assist device utilization. It is notable that despite differences in acuity of presentation and severity of illness at the time of implantation, the outcomes were similar among the 3 subgroups of PPCMP.
Survival with MCS has improved recently in both BTT 21 and DT patients. Unadjusted survival for women with PPCMP after MCS in our study was comparable with survival observed at 1 and 2 years post heart transplantation. 22 This robust survival was achieved despite high acuity of illness at presentation. A multivariable analysis was performed to resolve whether the superior unadjusted survival observed in the PPCMP group was because of factors inherent to the diagnosis of PPCMP or attributable to a more favorable risk profile in this group. The attenuation of the observed survival advantage after risk adjustment suggests that age and lower burden of comorbidities and not an intrinsic benefit conferred by PPCMP explain a good portion of the survival advantage.
The proportion of patients with PPCMP who were transplanted after 1 year was 29.8% and at 3 years was 48%, which was higher than observed in women with non-PPCMP. However, in a cohort such as the PPCMP patients who are young and with less comorbidity, a higher rate of transplantation might be expected. Only a proportion of 58% and 25% of the women with PPCMP who received MCS as BTT and BTC were able to achieve the goal of heart transplantation. The reason why a significant proportion of women with PPCMP remained on support and not transplanted is unclear, but could be related to conditions that precluded transplantation (eg, complications occurring subsequent to MCS, sensitization to human leukocyte antigen antibodies, or compliance issues).
Historically, reported in the literature ≈60% of all patients with PPCMP have improvement in myocardial dysfunction and 45% experience normalization of LV ejection fraction. [7] [8] [9] Hence, given the natural history of this disease, it is expected that patients who received MCS may have a higher potential for recovery of LV function. A recent report examining myocardial recovery in acute onset heart failure showed that 50% of patients who received left ventricular assist device (LVAD) recovered LV function and were explanted. 23 Of these, >90% patients remained free of transplantation at 19 months. Patients who achieve recovery have predominantly non-ICMP, are younger, and have a shorter duration of heart failure. 24, 25 Case reports of LV recovery and explanation of LVAD in PPCMP have been also published. 13, 26 Disappointingly in this large cohort, only 6% of PPCMP patients achieved recovery, which is not significantly higher than the rate observed in non-PPCMP patients. The explanation for this low frequency of recovery is unknown. It should be noted, however, that the PPCMP patients who did recover presented acutely or subacutely and in our cohort 60% of PPCMP who received MCS had chronic heart failure. The algorithms to evaluate for recovery of LV function in patients with MCS are not standardized among centers in the United States, thus we don't know whether patients were optimized in their heart failure medications post implant or whether recovery was actively evaluated with ramp down studies. In addition, oxidative stress has been associated with poor recovery in patients with PPCMP, 27 and recent data suggest elevated oxidative stress levels in LVAD-supported patients. 28 However, the contribution of this mechanism to the observed low rates of recovery is not known.
The pathogenesis of PPCMP remains unknown. Recent reports suggest that a cleaved product of prolactin has proapoptotic and antiangiogenic effects and may play a role in the development of PPCMP. 29 The blockage of prolactin with the dopamine agonist, bromocriptine, has been used in patients with PPCMP with some positive results. 30 Myocardial recovery and explantation of LVAD in a patient with PPCMP who received prolactin inhibitors have been described. 31 Bromocriptine has also been associated with an increased prothrombotic state, 32 thus given the propensity of thromboembolic events in patients with LVADs, the risk:benefit ratio of an strategy using prolactin inhibition in PPCMP patients while being supported with durable MCS to enhance myocardial recovery is uncertain.
PPCMP is frequently perceived as a rare and benign disease with high potential for recovery of heart function; however, despite the improved survival in PPCMP patients observed in this report. The fact that PPCMP is the underlying diagnosis in 7.9% of women receiving durable MCS and that only 6% is explanted, associated with prior publications reporting that 5% of all transplanted women had PPCMP as underlying diagnosis, 11 challenges this perception and underlines the need for newer therapeutic strategies in the management of these young women.
Limitations
The diagnosis of PPCMP is made following strict criteria, being of paramount importance the exclusion of other etiologies of heart failure. It is challenging for the clinician to determine whether a patient had unrecognized heart failure, which was just unmasked by pregnancy rather than truly PPCMP. This is particularly important in light of recent reports showing that patients diagnosed with PPCMP may have instead unrecognized underlying familial cardiomyopathy, 33 which entails a worse prognosis. Our report is a retrospective and registry study; we rely in the accurate diagnosis of PPCMP performed at the MCS implanting site.
We were unable to determine whether patients were getting optimal heart failure therapy or whether there were standardized protocols to assess for LV recovery while on LVAD support. Similarly, given that the INTERMACS database captures the implant strategy, we were unable to determine the reasons why significant proportion of women with PPCMP was not transplanted. Finally, the outcomes in PPCMP vary according to geographical location, thus the results of this study may not apply globally.
Conclusions
In summary, end-stage PPCMP women who receive durable MCS have a better survival than women with non-PPCPM. The improved survival observed in PPCMP is likely related to age and comorbidities. In spite of being a younger and lesser comorbid cohort, less than half of the PPCMP patients achieved heart transplantation. Although PPCMP patients had many favorable characteristics, myocardial recovery was uncommon.
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